Scleroderma News

PHILADELPHIA — Nearly 60% of women with systemic sclerosis reported that their sexuality was negatively impacted by their disease, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Rituximab is comparable in terms of safety and efficacy to cyclophosphamide among patients with interstitial lung disease associated with connective tissue diseases, according to data presented at ACR Convergence 2022.

PHILADELPHIA — A novel risk score accurately predicted interstitial lung disease in patients with systemic sclerosis at the time of diagnosis, which may reduce unnecessary CT screening, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Immunosuppressive or anti-fibrotic drugs do not appear to have any clear impact on worsening gastrointestinal symptoms in patients with early systemic sclerosis, according to data presented at ACR Convergence 2022.

Patients with systemic sclerosis demonstrate a “markedly higher risk” for heart failure, but not asymptomatic ventricular dysfunction, compared with those without the disease, according to data published in Arthritis Care & Research.

Patients with autoimmune diseases may be at higher risk for cardiovascular disease than patients without autoimmune diseases, according to data published in The Lancet.

Despite advances in understanding and diagnostics, patients with systemic sclerosis still demonstrate “significantly higher” mortality rates compared with the general population, according to Swedish data published in Rheumatology.

SAN DIEGO — A clear intervention plan and collaboration with pulmonology are key to managing patients with interstitial lung disease in autoimmune conditions, according to a speaker at the Congress of Clinical Rheumatology West.

SAN DIEGO — Pulmonary arterial hypertension’s prevalence and rate of progression in patients with connective tissue diseases should make regular screening a priority, according to a speaker at the Congress of Clinical Rheumatology West.

SAN DIEGO — Patients with systemic sclerosis will likely require multidisciplinary management with combination therapy to treat the myriad complications that may arise, according to a speaker at the Congress of Clinical Rheumatology West.